BioSpace News Archive

The signing ceremony for CStone Pharmaceuticals’ Global R&D Headquarters and Industrialization Base took place in Suzhou on August 6.

NovaBay® Pharmaceuticals, Inc., a biopharmaceutical company focusing on commercializing Avenova for the domestic eye care market, reports financial results for the three and six months ended June 30, 2019 and provides a business update.

AstraZeneca and Merck, known as MSD outside the United States and Canada, announced positive results from the Phase 3 PROfound trial of LYNPARZA in men with metastatic castration-resistant prostate cancer who have an homologous recombination repair gene mutation and have progressed on prior treatment with new hormonal anticancer treatments.

Investment Includes Equity and Corteva’s Shares in Taxon Biosciences for Shares in Lavie Bio

Bausch Health Companies Inc. (NYSE/TSX: BHC) and its dermatology business, Ortho Dermatologics, one of the largest prescription dermatology health care businesses, today announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for IDP-123 (tazarotene 0.045%)

Second quarter 2019 revenue of $131 million

Presentation scheduled for 2:30 pm ET on August 14, 2019

Phase 2 Personalized Cancer Vaccine (mRNA-4157) study initiated, with first patient consented

Awarded the second phase of a contract to develop a field-deployable Anthrax diagnostic assay and expand the research to an antimicrobial resistance diagnostic assay.

Initiation of single, pivotal, 12-week, Phase 3 gMG clinical trial on track for the second half of 2019